Source: Annual Congress 2005 - Asthma and COPD: management and burden
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Magnan, C. Pribil, M. Daniloski, F. Becret, F. A. Allaert (Marseille, Marly-le-Roi, Rouen, Dijon, France). Influence of age on evolution of asthma control level and treatment compliance under ICS/LABA therapy. Eur Respir J 2005; 26: Suppl. 49, 2457

Member's Comments

No comment yet.

Related content which might interest you: Does the choice of ICS/LABA regimen influence exacerbation rates in asthma patients with high as-needed use? Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Impact of omalizumab treatment persistence on asthma control Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Stability and achievement of asthma control with higher doses of inhaled conticosteroids regular treatment Source: Annual Congress 2011 - Asthma management and response Year: 2011 CAPTAIN: Effects of age on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 The response to combination therapy treatment regimens in severe/difficult-to-treat asthma Source: Eur Respir J 2008; 32: 1237-1242 Year: 2008 Variation of regular maintenance therapy with budesonide/formoterol of children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008 Asthma control and lung function after step down from high dose ICS/LABA combination therapy Source: Annual Congress 2011 - Asthma management and response Year: 2011 CAPTAIN: Effects of smoking status on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA) Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Predictive factors for asthma control according to ACQ5 in asthma patients treated with budesonide/formoterol maintenance and reliever therapy. Results from the EuroSMART study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Influence of treatment by single combined inhaler on adherence of patients with asthma Source: Annual Congress 2009 - Respiratory physiology Year: 2009 Stability of overall asthma control achieved with budesonide/formoterol maintenance + reliever therapy Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009 Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 616s Year: 2007 Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018 Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Asthma control and medication use five years after early or delayed introduction of inhaled corticosteroids in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003